Noninvasive assessment of radiation-induced renal injury in mice.
Radiobiology
irradiation
mouse
renal damage
Journal
International journal of radiation biology
ISSN: 1362-3095
Titre abrégé: Int J Radiat Biol
Pays: England
ID NLM: 8809243
Informations de publication
Date de publication:
2021
2021
Historique:
pubmed:
20
1
2021
medline:
23
9
2021
entrez:
19
1
2021
Statut:
ppublish
Résumé
The kidney is a radiosensitive late-responding normal tissue. Injury is characterized by radiation nephropathy and decline of glomerular filtration rate (GFR). The current study aimed to compare two rapid and cost-effective methodologies of assessing GFR against more conventional biomarker measurements. C57BL/6 mice were treated with bilateral focal X-irradiation (1x14Gy or 5x6Gy). Functional measurements of kidney injury were assessed 20 weeks post-treatment. GFR was estimated using a transcutaneous measurement of fluorescein-isothiocyanate conjugated (FITC)-sinistrin renal excretion and also dynamic contrast-enhanced CT imaging with a contrast agent (ISOVUE-300 Iopamidol). Hematoxylin and eosin (H&E) and Periodic acid-Schiff staining identified comparable radiation-induced glomerular atrophy and mesangial matrix accumulation after both radiation schedules, respectively, although the fractionated regimen resulted in less diffuse tubulointerstitial fibrosis. Albumin-to-creatinine ratios (ACR) increased after irradiation (1x14Gy: 100.4 ± 12.2 µg/mg; 6x5Gy: 80.4 ± 3.02 µg/mg) and were double that of nontreated controls (44.9 ± 3.64 µg/mg). GFR defined by both techniques was negatively correlated with BUN, mesangial expansion score, and serum creatinine. The FITC-sinistrin transcutaneous method was more rapid and can be used to assess GFR in conscious animals, dynamic contrast-enhanced CT imaging technique was equally safe and effective. This study demonstrated that GFR measured by dynamic contrast-enhanced CT imaging is safe and effective compared to transcutaneous methodology to estimate kidney function.
Identifiants
pubmed: 33464992
doi: 10.1080/09553002.2021.1876950
pmc: PMC8352084
mid: NIHMS1722610
doi:
Substances chimiques
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
664-674Subventions
Organisme : NCI NIH HHS
ID : R01 CA227493
Pays : United States
Références
J Clin Oncol. 2011 Jun 10;29(17):2416-23
pubmed: 21555692
Br J Radiol. 1986 Jun;59(702):587-95
pubmed: 3708268
Nephrol Dial Transplant. 2009 Oct;24(10):2997-3001
pubmed: 19461009
PLoS One. 2013 Nov 18;8(11):e79992
pubmed: 24260332
Nephron. 1993;64(4):626-35
pubmed: 8366991
J Vis Exp. 2018 Oct 21;(140):
pubmed: 30394397
Nucl Med Biol. 2014 Feb;41(2):210-5
pubmed: 24388044
Clin J Am Soc Nephrol. 2012 Sep;7(9):1416-27
pubmed: 22822016
J Pharmacol Toxicol Methods. 2013 May-Jun;67(3):187-93
pubmed: 23376812
Cell Biol Int. 1996 Jan;20(1):15-27
pubmed: 8936403
Nephron. 1998 Aug;79(4):408-12
pubmed: 9689155
Nat Med. 2011 Jul 31;17(8):952-60
pubmed: 21804539
Kidney Int Suppl. 2010 Dec;(119):S22-6
pubmed: 21116313
Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1436-43
pubmed: 18355974
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1249-56
pubmed: 7713786
Clin Physiol. 1985 Feb;5(1):1-17
pubmed: 3882316
Radiat Oncol. 2014 Nov 26;9:253
pubmed: 25424613
Am J Physiol Renal Physiol. 2012 Sep;303(5):F783-8
pubmed: 22696603
J Transl Med. 2013 Jan 15;11:17
pubmed: 23320604
Semin Oncol. 2013 Dec;40(6):757-73
pubmed: 24331195
Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):810-21
pubmed: 12095546
Semin Nephrol. 2010 Nov;30(6):627-34
pubmed: 21146127
Kidney Int Suppl (2011). 2014 Nov;4(1):9-15
pubmed: 26312144
Oncotarget. 2016 Apr 5;7(14):18825-36
pubmed: 26958942
Nephrology (Carlton). 2015 Mar;20(3):117-23
pubmed: 25388805
Semin Radiat Oncol. 2007 Apr;17(2):81-8
pubmed: 17395038
Eur J Cancer. 1993;29A(16):2239-43
pubmed: 8110493
J Clin Invest. 2009 Apr;119(4):943-53
pubmed: 19287096
Am J Physiol. 1986 Dec;251(6 Pt 2):H1324-32
pubmed: 3789184
FASEB J. 2017 Feb;31(2):771-780
pubmed: 27836988
Cochrane Database Syst Rev. 2013 Oct 08;(10):CD008944
pubmed: 24101439
Q J Med. 1953 Apr;22(86):215-42
pubmed: 13056165
Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22
pubmed: 2032882
Radiother Oncol. 1991 Aug;21(4):277-81
pubmed: 1924867
FASEB J. 2020 Jun;34(6):7915-7926
pubmed: 32293077
Curr Radiopharm. 2015;8(1):49-55
pubmed: 25506705
Radiother Oncol. 2013 Sep;108(3):464-8
pubmed: 23849167
Int J Radiat Oncol Biol Phys. 1988 Apr;14(4):751-9
pubmed: 3350731
Med Phys. 2017 Sep;44(9):4786-4794
pubmed: 28627007
J Nucl Med. 2010 Jul;51(7):1049-58
pubmed: 20554737
Int J Radiat Biol. 1989 Oct;56(4):449-62
pubmed: 2571658
PLoS One. 2013 Aug 19;8(8):e71519
pubmed: 23977062
Kidney Int. 2007 Feb;71(3):266-71
pubmed: 17149371
Med Phys. 2017 Sep;44(9):4795-4803
pubmed: 28626876
Kidney Int. 2011 Jun;79(11):1254-8
pubmed: 21368744
Nucl Med Commun. 2007 Jul;28(7):547-53
pubmed: 17538396
Cancer. 2007 Sep 15;110(6):1376-84
pubmed: 17634949
Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266
pubmed: 11904577
Nat Rev Nephrol. 2009 Aug;5(8):450-62
pubmed: 19564889
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S108-15
pubmed: 20171504
Semin Nephrol. 2003 Sep;23(5):486-99
pubmed: 13680538
Semin Hematol. 2012 Jan;49(1):73-82
pubmed: 22221787